A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels - PubMed (original) (raw)
. 2005 May 1;14(9):1199-210.
doi: 10.1093/hmg/ddi131. Epub 2005 Mar 24.
Affiliations
- PMID: 15790598
- DOI: 10.1093/hmg/ddi131
A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels
Elizabeth C Wolstencroft et al. Hum Mol Genet. 2005.
Abstract
Spinal muscular atrophy (SMA) is caused by homozygous loss of the survival motor neuron (SMN1) gene. In virtually all SMA patients, a nearly identical copy gene is present, SMN2. SMN2 cannot fully compensate for the loss of SMN1 because the majority of transcripts derived from SMN2 lack a critical exon (exon 7), resulting in a dysfunctional SMN protein. Therefore, the critical distinction between a functional and a dysfunctional SMN protein is the inclusion or the exclusion of the exon 7 encoded peptide. To determine the role of the 16 amino acids encoded by SMN exon 7, a panel of synthetic mutations were transiently expressed in SMA patient fibroblasts and HeLa cells. Consistent with previous reports, the protein encoded by SMN exons 1-6 was primarily restricted to the nucleus. However, a variety of heterologous sequences fused to the C-terminus of SMN exons 1-6 allowed mutant SMN proteins to properly distribute to the cytoplasm and to the nuclear gems. These data demonstrate that the SMN exon 7 sequence is not specifically required, rather this region functions as a non-specific 'tail' that facilitates proper localization. Therefore, a possible means to restore additional activity to the SMNDelta7 protein could be to induce a longer C-terminus by suppressing recognition of the native stop codon. To address this possibility, aminoglycosides were examined for their ability to restore detectable levels of SMN protein in SMA patient fibroblasts. Aminoglycosides can suppress the accurate identification of translation termination codons in eukaryotic cells. Consistent with this, treatment of SMA patient fibroblasts with tobramycin and amikacin resulted in a quantitative increase in SMN-positive gems and an overall increase in detectable SMN protein. Taken together, this work describes the role of the critical exon 7 region and identifies a possible alternative approach for therapeutic intervention.
Similar articles
- Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector.
Baughan T, Shababi M, Coady TH, Dickson AM, Tullis GE, Lorson CL. Baughan T, et al. Mol Ther. 2006 Jul;14(1):54-62. doi: 10.1016/j.ymthe.2006.01.012. Epub 2006 Mar 31. Mol Ther. 2006. PMID: 16580882 - Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J. Thurmond J, et al. J Med Chem. 2008 Feb 14;51(3):449-69. doi: 10.1021/jm061475p. Epub 2008 Jan 19. J Med Chem. 2008. PMID: 18205293 - Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y, Grimmler M, Schwarzer V, Schoenen F, Fischer U, Wirth B. Sun Y, et al. Hum Mutat. 2005 Jan;25(1):64-71. doi: 10.1002/humu.20111. Hum Mutat. 2005. PMID: 15580564 - Spinal muscular atrophy: from gene to therapy.
Wirth B, Brichta L, Hahnen E. Wirth B, et al. Semin Pediatr Neurol. 2006 Jun;13(2):121-31. doi: 10.1016/j.spen.2006.06.008. Semin Pediatr Neurol. 2006. PMID: 17027862 Review. - Animal models of spinal muscular atrophy.
Schmid A, DiDonato CJ. Schmid A, et al. J Child Neurol. 2007 Aug;22(8):1004-12. doi: 10.1177/0883073807305667. J Child Neurol. 2007. PMID: 17761656 Review.
Cited by
- Nonsense suppression therapies in human genetic diseases.
Martins-Dias P, Romão L. Martins-Dias P, et al. Cell Mol Life Sci. 2021 May;78(10):4677-4701. doi: 10.1007/s00018-021-03809-7. Epub 2021 Mar 22. Cell Mol Life Sci. 2021. PMID: 33751142 Free PMC article. Review. - A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo.
Dickson A, Osman E, Lorson CL. Dickson A, et al. Hum Gene Ther. 2008 Nov;19(11):1307-15. doi: 10.1089/hum.2008.067. Hum Gene Ther. 2008. PMID: 19848583 Free PMC article. - Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.
Du M, Keeling KM, Fan L, Liu X, Kovaçs T, Sorscher E, Bedwell DM. Du M, et al. J Mol Med (Berl). 2006 Jul;84(7):573-82. doi: 10.1007/s00109-006-0045-5. Epub 2006 Mar 16. J Mol Med (Berl). 2006. PMID: 16541275 - Spinal muscular atrophy disease: a literature review for therapeutic strategies.
Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L. Stavarachi M, et al. J Med Life. 2010 Jan-Mar;3(1):3-9. J Med Life. 2010. PMID: 20302191 Free PMC article. Review. - Therapy development for spinal muscular atrophy in SMN independent targets.
Tsai LK. Tsai LK. Neural Plast. 2012;2012:456478. doi: 10.1155/2012/456478. Epub 2012 May 31. Neural Plast. 2012. PMID: 22701806 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical